NCT06142617View on ClinicalTrials.gov

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

June 30, 2028

Conditions
Non Small Cell Lung CancerImmune Checkpoint InhibitorEGFR Exon 21 Mutation
Interventions
DRUG

Pembrolizumab, pemetrexed, platinum

Four cycles of platinum and pemetrexed in combination with pembrolizumab will be administered as first line therapy and up to 31 cycles pemetrexed and pembrolizumab maintenance therapy every 3 weeks.

DRUG

Osimertinib

Osimertinib will be the sequential treatment strategy at progression until resistance develops.

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06142617 - A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. | Biotech Hunter | Biotech Hunter